Fig. 10. Comparison of ⁸⁹Zr activity associated with blood pool and bone (%ID g^–1) for animals administered ⁸⁹Zr-YM103-trastuzumab and ⁸⁹Zr-DFO-trastuzumab, determined by ex vivo biodistributions. At 7 days PI, bone uptake is higher than blood retention for animals administered ⁸⁹Zr-YM103-trastuzumab, whereas for animals administered ⁸⁹Zr-DFO-trastuzumab, activity in blood is higher than that associated with bone.